Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

Michael O'Riordan

December 01, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Michael O'Riordan

December 01, 2016

News Conference News AHA 2016

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Daily News

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Michael O'Riordan

November 01, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

AHA 提供他汀类药物和心血管药物药物相互作用指导

Michael O'Riordan

October 18, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

Advertisement

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

AHA 提供他汀类药物和心血管药物药物相互作用指导

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content